Search

Your search keyword '"Alison L. Baird"' showing total 20 results
Start Over Author "Alison L. Baird" Publisher wiley
20 results on '"Alison L. Baird"'

1. Blood protein predictors of brain amyloid for enrichment in clinical trials?

Author

Nicholas J. Ashton, Steven J. Kiddle, John Graf, Malcolm Ward, Alison L. Baird, Abdul Hye, Sarah Westwood, Karyuan Vivian Wong, Richard J. Dobson, Gil D. Rabinovici, Bruce L. Miller, Howard J. Rosen, Andrew Torres, Zhanpan Zhang, Lennart Thurfjell, Antonia Covin, Cristina Tan Hehir, David Baker, Chantal Bazenet, Simon Lovestone, and AIBL Research Group

Subjects
Plasma, β amyloid, Proteomics, Alzheimer's disease, Biomarker, Fibrinogen γ‐chain, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Background Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood‐based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large‐scale prevention trials. Methods Nontargeted proteomic discovery was applied to 78 subjects from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing with a range of NAB values. Technical and independent replications were performed by immunoassay. Results Seventeen discovery candidates were selected for technical replication. α2‐Macroglobulin, fibrinogen γ‐chain (FGG), and complement factor H‐related protein 1 were confirmed to be associated with NAB. In an independent cohort, FGG plasma levels combined with age predicted NAB had a sensitivity of 59% and specificity of 78%. Conclusion A single blood protein, FGG, combined with age, was shown to relate to NAB and therefore could have potential for enrichment of clinical trial populations.

Published
2015
Full Text
View/download PDF

2. Identification of plasma proteome signatures associated with ATN framework using SOMAscan

Author

Isabelle Bos, Simon Lovestone, Mara ten Kate, Ellen De Roeck, Lars Bertram, Giovanni B. Frisoni, Daniel Alcolea, Nicholas J. Ashton, Frederik Barkhof, Gwendoline Peyratout, Frans R.J. Verhey, Yvonne Freund, Noel J. Buckley, Sebastiaan Engelborghs, Fabian Kilpert, Valerija Dobricic, Régis Bordet, Paul Morgan, Mikel Tainta, Johannes Streffer, José Luis Molinuevo, Silvy Gabel, Kaj Blennow, Rik Vandenberghe, Kristel Sleegers, Olivier Blin, Cristina Legido-Quigley, Alberto Lleó, Abdul Hye, Andreas G. Franke, Alejo J. Nevado-Holgado, Julius Popp, Lutz Frölich, Sarah Westwood, Magda Tsolaki, Karen Meersmans, Laura Winchester, Liu Shi, Anders Wallin, Lorena Rami, Jill C. Richardson, Henrik Zetterberg, Stephanie J.B. Vos, Philip Scheltens, Alison L. Baird, Pablo Martinez-Lage, Peter Johannsen, Angharad R. Morgan, Pieter Jelle Visser, Charlotte E. Teunissen, Petronella Kettunen, and Shengjun Hong

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Proteome, Identification (biology), Neurology (clinical), Computational biology, Geriatrics and Gerontology, Biology
Published
2020

3. F1‐02‐01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT‐LIGHT AND YKL‐40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF‐AD MULTIMODAL BIOMARKER DISCOVERY STUDY

Author

Pablo Martinez-Lage, Ulf Andreasson, Frederik Barkhof, Rik Vandenberghe, Henrik Zetterberg, Régis Bordet, Stephanie J.B. Vos, Cristina Legido-Quigley, Alberto Lleó, Frans R.J. Verhey, Philip Scheltens, Jill C. Richardson, Alison L. Baird, Peter Johannsen, Giovanni B. Frisoni, Lutz Frölich, Simon Lovestone, Lars Bertram, Pieter Jelle Visser, Johannes Streffer, Isabelle Bos, Olivier Blin, Yvonne Freund-Levi, Kaj Blennow, Sebastiaan Engelborghs, Julius Popp, and Magda Tsolaki

Subjects
Epidemiology, business.industry, Health Policy, Neurofilament light, Cognition, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Neurogranin, Geriatrics and Gerontology, Biomarker discovery, business, Neuroscience
Published
2018

4. P2‐458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY

Author

Viktor Wottschel, Enrico Peira, Jérôme Revillard, Mark Forrest Gordon, Rik Vandenberghe, Gerald Novak, Anders Wallin, Zhiyong Xie, Jill C. Richardson, Stephanie J.B. Vos, Philip Scheltens, Frans R.J. Verhey, Giovanni B. Frisoni, Silvia Ingala, Sebastiaan Engelborghs, Julius Popp, Simon Lovestone, José Luis Molinuevo, Lars Bertram, Henrik Zetterberg, Alison L. Baird, Olivier Blin, Magda Tsolaki, Pieter Jelle Visser, Mara ten Kate, Frederik Barkhof, Pablo Martinez-Lage, Régis Bordet, Johannes Streffer, Isabelle Bos, Cristina Legido-Quigley, and Alberto Redolfi

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, Medicine, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, Biomarker discovery, business
Published
2018

5. F1‐02‐04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF‐AD MULTIMODAL BIOMARKER DISCOVERY STUDY

Author

Johannes Streffer, Isabelle Bos, Katie Lunnon, Pablo Martinez-Lage, Fahri Küçükali, Giovanni B. Frisoni, Simon Lovestone, Kristel Sleegers, Lars Bertram, Frederik Barkhof, Rik Vandenberghe, Lutz Frölich, Sebastiaan Engelborghs, Julius Popp, Frans R.J. Verhey, Henrik Zetterberg, Alison L. Baird, Olivier Blin, Rebecca G. Smith, Valerija Dobricic, Magda Tsolaki, Shengjun Hong, Christine Van Broeckhoven, Régis Bordet, Alberto Lleó, Philip Scheltens, Peter Johannsen, Fabian Kilpert, Stephanie J.B. Vos, Cristina Legido Quigley, Pieter Jelle Visser, and Jill C. Richardson

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Genomics, Neurology (clinical), Computational biology, Geriatrics and Gerontology, Biomarker discovery, Biology, Epigenomics
Published
2018

6. F1‐02‐02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION

Author

Johannes Streffer, Frederik Barkhof, Anders Wallin, Alejo J. Nevado-Holgado, Rik Vandenberghe, Alison L. Baird, Stuart G. Snowden, Cristina Legido-Quigley, Giovanni B. Frisoni, Paul Morgan, Samuel Touchard, Isabelle Bos, Stephanie J.B. Vos, José Luis Molinuevo, Abdul Hye, Sneha N Anand, Angharad R. Morgan, Pieter Jelle Visser, Julius Popp, Nicholas J. Ashton, Sarah Westwood, Liu Shi, Sebastiaan Engelborghs, Andrey Kormilitzin, Alberto Lleó, Philip Scheltens, Pablo Martinez-Lage, Henrik Zetterberg, Simon Lovestone, and Lars Bertram

Subjects
Epidemiology, business.industry, Health Policy, Extension study, Disease progression, Bioinformatics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Replication (statistics), Medicine, Amyloid burden, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

7. F1‐02‐03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF‐AD BIOMARKER DISCOVERY STUDY

Author

Pablo Martinez-Lage, Anders Wallin, Enrico Peira, Mark Forrest Gordon, Rik Vandenberghe, Jérôme Revillard, Mara ten Kate, Jill C. Richardson, Pieter Jelle Visser, Olivier Blin, Isabelle Bos, Giovanni B. Frisoni, Julius Popp, Cristina Legido-Quigley, Henrik Zetterberg, Zhiyong Xie, Alberto Redolfi, Frans R.J. Verhey, Alison L. Baird, Frederik Barkhof, Simon Lovestone, Stephanie J.B. Vos, Sebastiaan Engelborghs, Lars Bertram, Philip Scheltens, Johannes Streffer, Magda Tsolaki, José Luis Molinuevo, Régis Bordet, and Gerald Novak

Subjects
Amyloid pathology, Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, Biomarker discovery, business
Published
2018

8. P3‐233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF‐AD BIOMARKER DISCOVERY COHORT

Author

Min Kim, Abdul Hye, Pablo Martinez-Lage, Rik Vandenberghe, José Luis Molinuevo, Alison L. Baird, Alejo J. Nevado-Holgado, Cristina Legido-Quigley, Tahmina Ahmad, Isabelle Bos, Stuart G. Snowden, Petroula Proitsi, Johannes Streffer, Julius Popp, Frederik Barkhof, Giovanni B. Frisoni, Sarah Westwood, Alberto Lleó, Anders Wallin, Sebastiaan Engelborghs, Nicholas J. Ashton, Pieter Jelle Visser, Simon Lovestone, Lars Bertram, Stephanie J.B. Vos, Henrik Zetterberg, and Philip Scheltens

Subjects
Primary (chemistry), Amyloid, Epidemiology, business.industry, Health Policy, Disease progression, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cohort, Cancer research, Medicine, Neurology (clinical), Geriatrics and Gerontology, Biomarker discovery, business
Published
2018

9. [P2–223]: MARKERS OF CIRCADIAN CLOCK FUNCTION IN ALZHEIMER's DISEASE

Author

Alison L. Baird, Sneha N Anand, and Simon Lovestone

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Circadian clock, Neurology (clinical), Disease, Geriatrics and Gerontology, Biology, Neuroscience, Function (biology)
Published
2017

10. [F1–02–02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION

Author

Richard Dobson, Alejo J. Nevado-Holgado, Torben Kimhofer, Anders Wallin, Frederik Barkhof, Pablo Martinez-Lage, Anoushka Leslie, Julius Popp, Natalja Kurbatova, Alison L. Baird, Sarah Westwood, Beatriz Jiménez, Giovanni B. Frisoni, Cristina Legido-Quigley, Nicholas J. Ashton, Stephanie J.B. Vos, Lynn Maslen, Abdul Hye, Jake T M Pearce, Pieter Jelle Visser, Ellie D’Hondt, Olivia Kowalczyk, Stuart G. Snowden, Eric Westman, Rik Vandenberghe, Henrik Zetterberg, Alberto Lleó, Matthew R. Lewis, Wilfried Verachtert, Benjamine Young Liu, David Ruvolo, Philip Scheltens, María Gómez-Romero, Danai Dima, Luke Whiley, Petroula Proitsi, Mark David, Nicola Voyle, Elaine Holmes, Sebastiaan Engelborghs, Johannes Streffer, Isabelle Bos, Toby J. Athersuch, Simon Lovestone, Lars Bertram, José Luis Molinuevo, and Tom Ashby

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Genomics, Disease, medicine.disease, Proteomics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cohort, medicine, Dementia, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, Biomarker discovery, business
Abstract

Background Biomarkers of Alzheimer’s disease (AD) pathology and progression have now been identified across various modalities. The aims of the two studies presented (ANM-MMB and EMIF-AD biomarker discovery) are to discover and replicate previously identified biomarkers of disease pathology and progression, and moreover to determine whether a multimodal biomarker signature may add value in comparison to a biomarker of a single modality. Methods The ANM-MMB cohort is comprised of 718 AD, MCI converters and non-converters, and control subjects selected from the AddNeuroMed, Alzheimer’s research trust and Dementia case register cohorts. Cognitive measures, serum and urine metabolomics, structural MRI, genomics, whole blood transcriptomics and plasma proteomics data was available. The EMIF-AD biomarker discovery cohort consists of 1221 AD, MCI and control subjects, selected from the EMIF catalogue. All subjects had existing amyloid measures (CSF Aβ or amyloid-PET), structural MRI and clinical data, and furthermore plasma proteomics (targeted and untargeted), CSF proteomics (targeted), metabolomics, genomics and epigenetics data were generated. For both studies univariate and multivariate statistics were utilised to identify candidate biomarkers of AD pathology (neurodegeneration and/or brain amyloid burden), rates of cognitive decline, and MCI progression to dementia. pQTL-eQTL-mQTL analyses, network/pathway analysis, and multimodal classifiers were employed to detect multimodal signatures. Results Initial analyses indicate that in the ANM-MMB study a serum and urine derived 15 metabolite classifier predicts MCI progression to AD with 72% accuracy, and the biological significance of the metabolites included in the biomarker panel was identified. Further analyses will examine whether a multimodal classifier is able to predict with even greater accuracy. We will then seek to replicate this in the EMIF-AD biomarker discovery study. Further analyses will also examine single and multimodal biomarker classifiers of other endophenotypes. Conclusions These two studies could be used to identify novel and replicate previously identified single modality biomarker findings. Furthermore the impact of combining the additional modalities with these findings will be discussed. Computational and technical challenges encountered and the bioinformatics pipeline devised in the multimodal analysis of the ANM-MMB cohort will be used to inform the analysis pipeline of the EMIF-AD biomarker discovery study as a replication.

Published
2017

11. [P2–212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF‐AD): THE BIOMARKER DISCOVERY STUDY

Author

Isabelle Bos, Alberto Lleó, Johannes Streffer, Frederik Barkhof, Alison L. Baird, Pieter Jelle Visser, Philip Scheltens, Pablo Martinez-Lage, Rik Vandenberghe, Simon Lovestone, Lars Bertram, Henrik Zetterberg, Sebastiaan Engelborghs, Cristina Legido-Quigley, José Luis Molinuevo, Julius Popp, Stephanie J.B. Vos, Anders Wallin, and Giovanni B. Frisoni

Subjects
Epidemiology, business.industry, Health Policy, Medical information, Disease, Computational biology, Bioinformatics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, Biomarker discovery, business
Published
2017

12. [P1–289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID‐PET) IN THE EMIF‐AD BIOMARKER DISCOVERY COHORT

Author

Isabelle Bos, Alison L. Baird, Cristina Legido-Quigley, Abdul Hye, Henrik Zetterberg, Frederik Barkhof, Rik Vandenberghe, Johannes Streffer, Philip Scheltens, Alberto Lleó, Pieter Jelle Visser, Sebastiaan Engelborghs, Simon Lovestone, Lars Bertram, José Luis Molinuevo, Stuart G. Snowden, Julius Popp, Sarah Westwood, Pablo Martinez-Lage, Anders Wallin, Stephanie J.B. Vos, and Giovanni B. Frisoni

Subjects
Epidemiology, business.industry, Health Policy, Extension study, Amyloid pet, Bioinformatics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Replication (statistics), Cohort, Medicine, Amyloid burden, Neurology (clinical), Geriatrics and Gerontology, Biomarker discovery, business
Published
2017

13. S4‐01‐01: Cross‐Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau

Author

Charlotte E. Teunissen, Daniela Galimberti, Abdul Hye, Alison L. Baird, Sarah Westwood, Cristina Tan Hehir, Keyur Desai, Benjamine Young Liu, Chantal Bazenet, Malcolm Ward, Steven J. Kiddle, David Baker, Ben Newton, John Frederick Graf, Simon Lovestone, Lucilla Parnetti, Nicholas J. Ashton, Alberto Lleó, Madhav Thambisetty, and Philip Scheltens

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Pathology, medicine.medical_specialty, Developmental Neuroscience, Amyloid, Epidemiology, business.industry, Health Policy, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2016

14. P3‐108: DISCOVERY AND VALIDATION OF PLASMA BIOMARKERS RELATING TO CSF MEASURES OF ALZHEIMER'S DISEASE PATHOLOGY

Author

Charlotte E. Teunissen, Chantal Bazenet, Simon Lovestone, Malcolm Ward, Sarah Westwood, Alison L. Baird, Nicholas J. Ashton, Madhav Thambisetty, and Philip Scheltens

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, education, food and beverages, Disease, Plasma biomarkers, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, University medical, Neurology (clinical), Geriatrics and Gerontology, business
Abstract

BIOMARKERS RELATING TO CSF MEASURES OF ALZHEIMER’S DISEASE PATHOLOGY Alison L. Baird, Nicholas Ashton, Sarah Westwood, Malcolm Ward, Chantal Bazenet, Madhav Thambisetty, Philip Scheltens, Charlotte Teunissen, Simon Lovestone, Kings College London, London, United Kingdom; Kings College London, Institute of Psychiatry, London, United Kingdom; King’s College London, London, United Kingdom; 4 National Institute on Aging, Baltimore, Maryland, United States; 5 VU University Medical Centre, Amsterdam, Netherlands. Contact e-mail: alison.baird@kcl.ac.uk

Published
2014

15. F5‐02‐02: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH GLOBAL AND REGIONAL BRAIN BETA‐AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE

Author

Malcolm Ward, Lennart Thurfjell, Zhanpan Zhang, Andrew S. Torres, Nicholas J. Ashton, Alison L. Baird, David Baker, Lance Macaulay, Abdul Hye, Cristina Tan-Hehir, Antonia Covin, Steven J. Kiddle, Richard Dobson, Chantal Bazenet, and Simon Lovestone

Subjects
medicine.medical_specialty, Epidemiology, Chemistry, Health Policy, Disease, Blood proteins, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Amyloid deposition, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Beta (finance)
Published
2014

16. P1‐166: DISTINCT BLOOD PROTEIN MARKERS ARE ASSOCIATED WITH BRAIN REGIONS OF EARLY AMYLOID DEPOSITION IN ALZHEIMER'S DISEASE

Author

Steven J. Kiddle, Nicholas J. Ashton, Richard Dobson, David Baker, Antonia Covin, John Frederick Graf, Cristina Tan-Hehir, Malcolm Ward, Abdul Hye, Alison L. Baird, Chantal Bazenet, Zhanpan Zhang, Simon Lovestone, Lance Macaulay, Andrew S. Torres, and Lennart Thurfjell

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Blood proteins, Biochemistry of Alzheimer's disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Amyloid deposition, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2014

17. P2‐059: Identification of blood‐based complement biomarkers in Alzheimer's disease

Author

Nicholas J. Ashton, Claire L. Harris, Simon Lovestone, Alison L. Baird, Mohammed Aiyaz, Abdul Hye, Paul Morgan, Martina Settlecker, Svetlana Hakobyan, Joanna Riddoch-Contreras, Alexandra Stretton, and Richard Dobson

Subjects
Epidemiology, business.industry, Health Policy, Computational biology, Disease, Complement (complexity), Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Identification (biology), Neurology (clinical), Geriatrics and Gerontology, Biomarker discovery, business
Published
2012

18. P2‐054: Predicting the progression of Alzheimer's disease by plasma‐based biomarkers

Author

Abdul Hye, Martina Sattlecker, Joanna Riddoch-Contreras, Nicholas J. Ashton, Malcolm Ward, Ian Pike, Alison L. Baird, Richard Dobson, and Simon Lovestone

Subjects
Oncology, medicine.medical_specialty, Univariate analysis, Analyte, Multivariate analysis, Epidemiology, Clinical Dementia Rating, business.industry, Health Policy, Coefficient of variation, Disease, medicine.disease, Plasma biomarkers, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business
Abstract

Background: Alzheimer’s disease (AD) is the most common form of dementia, at present there remains a need for accurate biomarkers that can predict disease progression. In recent years markers of prediction, early diagnosis and progression have been identified in plasma by our group. We have therefore selected a multiplexing approach using the immunobased MILLIPLEX MAP assays to validate our previously discovered biomarkers with the aim to identify a combination of markers that can predict disease progression. Methods: 430 Alzheimer’s disease subjects, 395 cognitively normal and 173 mild cognitively impairment subjects were recruited from 2 large multi-centre cohorts. EDTA plasma was collected and evaluated for 45 analytes, using immuno-based MILLIPLEX MAP assays. Samples were randomized, blinded to the clinical information and measured in duplicate. Results: The intra-assay precision was calculated as the coefficient of variation (%) for each analyte and was

Published
2012

19. P2‐408: Classification of Alzheimer's disease using multiplex plasma‐based biomarkers

Author

Martina Sattlecker, Joanna Riddoch-Contreras, Nicholas J. Ashton, Abdul Hye, Richard Dobson, Ian Pike, Alison L. Baird, Malcolm Ward, and Simon Lovestone

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Multiplex, Neurology (clinical), Geriatrics and Gerontology, business
Published
2012

20. S1‐02‐01: Multiplexed analysis of plasma in Alzheimer's disease

Author

Martina Sattlecker, Simon Lovestone, Alison L. Baird, Malcolm Ward, Abdul Hye, Nicholas J. Ashton, Ian Pike, Madhav Thambisetty, Richard Dobson, and Joanna Riddoch-Contreras

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Pathology, medicine.medical_specialty, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, medicine, Neurology (clinical), Disease, Geriatrics and Gerontology, business
Published
2012

Catalog

Books, media, physical & digital resources
See catalog results